What does Acumen Pharmaceuticals, Inc. do?
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta…
What is Acumen Pharmaceuticals, Inc.'s P/E and P/B ratio?
Acumen Pharmaceuticals, Inc. has a P/E ratio of -1.3 and a P/B ratio of 2.60.
What is Acumen Pharmaceuticals, Inc.'s debt-to-equity ratio?
Acumen Pharmaceuticals, Inc. has a debt-to-equity ratio of 0.55.
How much does Acumen Pharmaceuticals, Inc. owe compared with what it owns?
Acumen Pharmaceuticals, Inc. owes $0.51 for every $1 it owns (balance sheet Jun 2026), which is moderate.
What is Acumen Pharmaceuticals, Inc.'s Positivity rank?
Acumen Pharmaceuticals, Inc. is ranked #4,356 of 6,774 companies globally and #2,155 of 4,000 in United States on PositoAI, with a Positivity Score of 19,556.
Does Acumen Pharmaceuticals, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Acumen Pharmaceuticals, Inc..
Where can I read the latest news about Acumen Pharmaceuticals, Inc.?
Recent headlines about Acumen Pharmaceuticals, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Acumen Pharmaceuticals, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Acumen Pharmaceuticals, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.